serYmun Yeast Announces Preclinical Safety and Efficacy Data for Their Yeast-Based Vaccine Against Porcine Parvovirus (PPV)

HALLE/SAALE, Germany, February 27, 2023 / B3C newswire / -- serYmun Yeast GmbH (“serYmun”), an animal health vaccine development company based in Germany, announces the breakthrough in the development of their first pig vaccine candidate against porcine parvovirus. A controlled target animal study proved the protective immunisation of pigs against porcine parvovirus (PPV).

After two intramuscular injections of serYmun’s proprietary vaccine candidate, the group treated already showed high titres of serum neutralizing antibodies seven days after vaccination, and a second peak after booster immunization on day 21. In a positive control group, a recently launched commercial product of one of the leading animal health companies showed antibody titres at a comparable level. The negative control group did not show seroconversion.

The vaccinated animals did not show any adverse clinical effects, which indicates safety of the vaccine.

The yeast-based platform technology, in which specific antigens are expressed by genetically modified yeast cells, was developed by the R&D team of serYmun.

“I am extremely happy and proud that our team has been successful in developing this vaccine and its basic platform technology in only four years”, states Dr. Wilhelm von Trott zu Solz, co- founder and CEO of serYmun Yeast GmbH. “This encourages us to start the registration process in order to launch our PPV and other vaccines. Based on our technology, our vaccines will benefit animals, farmers and veterinarians enormously. Our vaccine platform allows to develop safe and polyvalent vaccines in a record time and at comparably very low costs”.

serYmun Yeast will be present at the Animal Health, Nutrition and Technology Innovation Conference in London, March 5-8, 2023.

Link to the press release

About serYmun Yeast GmbH
The company was founded in 2017 by five founding partners and has developed a vaccine technology platform for animals, based on a novel patent-protected gene technology in which yeast cells are genetically modified in order to express immunologically active antigens. The whole yeast is then be inactivated and used as a vaccine for animals.
serYmun Yeast GmbH is based in Bernburg/Saale, Germany.